3.12
-0.23(-6.87%)
Currency In USD
| Previous Close | 3.35 |
| Open | 3.3 |
| Day High | 3.41 |
| Day Low | 3.1 |
| 52-Week High | 5.55 |
| 52-Week Low | 2.51 |
| Volume | 34,555 |
| Average Volume | 20,806 |
| Market Cap | 9.5M |
| PE | 3.59 |
| EPS | 0.87 |
| Moving Average 50 Days | 3.07 |
| Moving Average 200 Days | 3.48 |
| Change | -0.23 |
If you invested $1000 in Kiora Pharmaceuticals, Inc. (KPRX) 10 years ago, it would be worth $0.14 as of May 09, 2025 at a share price of $3.12. Whereas If you bought $1000 worth of Kiora Pharmaceuticals, Inc. (KPRX) shares 5 years ago, it would be worth $1.81 as of May 09, 2025 at a share price of $3.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy
Newsfile
May 05, 2025 11:00 AM GMT
Encinitas, California--(Newsfile Corp. - May 5, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an estab
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
Newsfile
Apr 04, 2025 11:00 AM GMT
Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15
Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting
Newsfile
Mar 12, 2025 11:00 AM GMT
Encinitas, California--(Newsfile Corp. - March 12, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO-104 in a proliferative vitreoretinopathy (PVR) model was accepted